Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Endometrial Neoplasms 1Anus Neoplasms 1

Interventions

Cyclophosphamide 8pembrolizumab 7fludarabine 6aldesleukin 4Papillomavirus Vaccines 4Vaccines 3Radiotherapy 3Light Coagulation 3Biopsy 3spartalizumab 2fludarabine phosphate 2entinostat 2Watchful Waiting 2Vorinostat 2VGX-3100 2Trastuzumab 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Paclitaxel 2Observation 2Nivolumab 2Interleukin-2 2Interleukin-12 Subunit p35 2Early Intervention, Educational 2Drug Therapy 2Carboplatin 2Adoptive Transfer 2trastuzumab deruxtecan 1tislelizumab 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × alovudine × Gynecologic × Clear all
NCT01717391 2019-03-26

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

University of Iowa

Phase 2 Completed
36 enrolled 5 charts
GastrointestinalGenitourinaryGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡